Alfuzosin

CHEMBL709 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

389.4 g/mol

LogP

1.7

Phase

4

An alpha-1 adrenergic blocker that relaxes the muscles of the prostate and bladder neck, making it easier to urinate in men with benign prostatic hyperplasia (BPH). It improves urinary flow and reduces symptoms such as incomplete bladder emptying, frequent urination, and nighttime awakenings to urinate.

분자량

389.4000 g/mol

LogP

1.70

TPSA

112.00 Å²

리핀스키 5의 법칙

통과

치료 영역

Benign Prostatic Hyperplasia Cardiovascular Disease Respiratory Disease Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC

InChI

InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)

Molecular Formula

C19H27N5O4

HBD / HBA

2 / 8

회전 가능 결합

8

무거운 원자

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

An alpha-1 adrenergic blocker that relaxes the muscles of the prostate and bladder neck, making it easier to urinate in men with benign prostatic hyperplasia (BPH). It improves urinary flow and reduces symptoms such as incomplete bladder emptying, frequent urination, and nighttime awakenings to urinate.

Yes, Alfuzosin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL709. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2092. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Alfuzosin PillFYI에서

구조

핵심 데이터

분자식: C19H27N5O4
동의어: 3

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.